CliffBio
small molecule

REVUFORJ

REVUMENIB CITRATE

Loss of exclusivityDecember 2042latest FDA-listed patent expiry
CompanySyndax Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameREVUFORJ
Active ingredientREVUMENIB CITRATE
StrengthEQ 25MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

Listed patents

PatentExpiresType
12564590December 2042product
11479557June 2037product
10683302June 2037substance, product

Regulatory exclusivity

CodeExpires
ODE-502November 2031
ODE-504November 2031
ODE-505November 2031
NCENovember 2029

More from Syndax Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

REVUFORJ patent cliff — loss of exclusivity December 2042 | CliffBio